[Local tumor control of metastatic Merkel cell carcinoma in a 90-year-old woman].

4区医学 Q3 Medicine

Hautarzt Pub Date : 2021-12-01 Epub Date: 2021-03-24 DOI:10.1007/s00105-021-04799-0

Katja Dicke, Vasileios Dervenis, Axel Hauschild, Thomas Dirschka

引用次数: 0

Abstract

Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. Many people suffer early local recurrences and distant metastases. The anti-PDL1 (PDL1: programmed death ligand 1) antibody avelumab has been approved as first-line treatment for advanced MCC in Europe. It is also an alternative treatment for old and multimorbid patients.

查看原文本刊更多论文

[1例90岁妇女转移性默克尔细胞癌的局部肿瘤控制]。

默克尔细胞癌(MCC)是一种罕见的侵袭性皮肤癌。许多人出现早期局部复发和远处转移。抗PDL1 (PDL1:程序性死亡配体1)抗体avelumab已在欧洲被批准作为晚期MCC的一线治疗药物。它也是老年和多病患者的替代治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hautarzt 医学-皮肤病学

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Der Hautarzt is an internationally recognized journal informing all dermatologists working in practical or clinical environments about important developments in the field of dermatology including allergology, venereology and related areas. Comprehensive reviews on a specific topical issue focus on providing evidenced based information on diagnostics and therapy. Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange. Case reports feature interesting cases and aim at optimizing diagnostic and therapeutic strategies. Review articles under the rubric "Continuing Medical Education" present verified results of scientific research and their integration into daily practice.